Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$9.68M, compared with -$9.74M a year earlier. Trailing-twelve-month net income was -$17.83M.

Context

  • Net income amounted to 50.3% of revenue in FY2025, down 961.9 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$22.23M (-24.3%) for the fiscal year ending Dec 2026, a slowdown from the +76.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.68M-19.9% QoQ
Last fiscal yearDec 2025
-$17.89M+76.6% YoY
LTMMar 2026
-$17.83M+73.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.6%-4146.9%-4147.5 pp
1 year+76.6%-24.3%-100.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(17.89M) USD
Year-over-year change
+76.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's LTM Mar 2026 net income of -$17.83M is the 3rd highest of the 5 companies compared; the peer median is -$23.66M.
  • Its year-over-year change of +73.0% is the 2nd highest of 5, against a peer median of +44.7%.
  • Net income amounts to 48.0% of revenue for VRCA, versus a peer median of 61.9%.
VRCA Competitors Peer median
Net Income for VRCA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M +155.6%—61.9%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026-$12.78M +65.5%——
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-$17.83M +73.0%—48.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$34.55M +23.8%——
BOLDBoundless Bio, Inc.LTM Mar 2026-$55.99M +14.8%——
Peer median (excluding VRCA) -$23.66M+44.7%—61.9%

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12M9.03M5.12M7.57M35.58M
Cost of Revenue472K725K746K2.74M3.44M
Gross Profit11.53M8.31M4.38M4.83M32.14M
Gross Margin96.1%92.0%85.4%63.8%90.3%
Research & Development15.93M12.2M20.3M11.84M8.86M
Selling, General & Admin26.98M17.41M47.31M58.82M35.22M
Operating Expenses42.44M29.6M70.14M70.75M44.08M
Depreciation & Amortization472K718K836K1.27M781K
EBITDA(30.31M)(21.6M)(62.2M)(65.9M)(9.36M)
EBITDA Margin-252.6%-239.1%-1213.8%-871.0%-26.3%
Operating Income(30.91M)(21.3M)(65.76M)(65.92M)(11.94M)
Operating Margin-257.6%-235.8%-1283.4%-871.3%-33.6%
Interest Income123K476K2.74M1.42M929K
Interest Expense4.3M2.17M3.96M9.41M7.74M
Other Income / Expenses(4.17M)(3.19M)(1.24M)(10.66M)(5.95M)
Income Before Tax(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Pre-Tax Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
Income Tax Expense00000
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Net Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
EPS (Basic)(12.97)(7.17)(14.78)(14.78)(1.68)
EPS (Diluted)(12.97)(7.17)(14.78)(14.78)(1.68)
Weighted Avg Shares2.7M3.42M4.53M5.18M10.65M
Weighted Avg Shares (Diluted)2.7M3.42M4.53M5.18M10.65M

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.